Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

March 2025

Achievement of endoscopic remission after induction reduces hospitalization burden in Crohn’s Disease: findings from a pooled post hoc analysis of risankizumab and upadacitinib Phase III trials

J Crohns Colitis. 2025 Feb 4;19(2):jjae128. doi: 10.1093/ecco-jcc/jjae128.

Panaccione R,

Ma C,

Jairath V,

Dignass A,

Joshi N,

Clark R,

Smith Z,

Nunag D,

Panaccione et al. investigated the association between achievement of endoscopic remission following induction therapy and hospitalisation outcomes in Crohn’s disease. Patients achieving endoscopic remission at Week 12 experienced a 55% reduction in Crohn’s disease-related hospitalisation rates over the 52-week maintenance period. The results support endoscopic remission as an early therapeutic target.

Keywords:

February 2025

Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial

Lancet Gastroenterol Hepatol. 2025;10:210–221. doi: 10.1016/S2468-1253(24)00386-8.

Naik S,

Sands et al. evaluated tamuzimod, a selective sphingosine 1-phosphate receptor 1 modulator, in patients with moderately-to-severely active UC. At Week 13, clinical remission (defined as an MMS stool frequency subscore of ≤1, rectal bleeding subscore of 0, and endoscopic subscore ≤1, excluding friability) was achieved by 28% and 24% of patients receiving tamuzimod 60 mg and 30 mg, respectively, compared with 11% in the placebo group. The treatment was well tolerated; most AEs were mild or moderate.